Back grey_arrow_rt.gif
 
 
AMBRILIA PROVIDES UPDATE ON PPL-100 PARTNERSHIP WITH MERCK & CO, INC.
 
 
  Montreal, July xx, 2008 - Ambrilia Biopharma Inc. (TSX:AMB) today announced that it was advised by Merck & Co, Inc., that the HIV protease inhibitor PPL-100, also known as MK-8122, has been placed on a development hold pending outcome of additional basic science efforts to evaluate other PL-100 prodrugs and formulations options. Merck's decision to place a development hold on MK-8122 was made pursuant to the results of the recently completed single dose and multi dose studies in healthy volunteers. Merck is also further exploring development of potential back-up compounds. The exclusive license agreement between the companies entered into on October 12, 2006 provides for additional milestone-based cash payments and royalties on the future development and commercialization of each back-up compound and/or related compounds developed by Merck and which fall within the scope of the Ambrilia HIV protease inhibitor program.
 
"Ambrilia believes in the potential of PPL-100/MK-8122 and related compounds to offer advantages to HIV patients over the currently commercialized protease inhibitors," said Dr. Philippe Calais, President and CEO of Ambrilia. "Our partnership with Merck continues and we look forward to further progress on potential back-up compounds."
 
Dr. Calais continued, "Both companies remain focused on the partnership and determined to provide the best compounds available to help people with HIV/AIDS."
 
Protease inhibitors are a key component to the current HIV/AIDS standard of care, the Highly Active Anti-Retroviral Treatment (HAART) consisting of a cocktail of HIV medicines.
 
About the Ambrilia and Merck Partnership
 
In October 2006, Ambrilia entered into an exclusive licensing agreement granting Merck & Co. - through an affiliate - the worldwide rights to its HIV protease inhibitor program, including lead compound PPL-100. In return, Ambrilia received an upfront payment of $US 17 million and is eligible for potential cash payments totaling $US212 million upon successful completion of development, clinical, regulatory and sales milestones, and royalties on all future product sales. The agreement also provides for additional milestone-based cash payments and royalties on the future development and commercialization of each back-up compound and/or related compounds developed by Merck and which fall within the scope of the Ambrilia HIV protease inhibitor program.
 
 
 
 
  icon paper stack View Older Articles   Back to Top   www.natap.org